Cargando…
Feasibility of Reduced Clinical Monitoring in Patients with Inflammatory Bowel Disease Treated with Thiopurine Therapy
BACKGROUND: Outpatient visits and laboratory assessments are routinely scheduled every 3 to 4 months in thiopurine-treated patients with inflammatory bowel disease (IBD) to timely detect thiopurine-related adverse events (AEs). AEs that require therapy adjustment beyond 12 months of treatment are ra...
Autores principales: | Jansen, Fenna M., Smits, Lisa J. T., Thomas, Pepijn W. A., de Jong, Dirk J., Kreijne, Joany E., van Dop, Willemijn A., den Broeder, Nathan, Hoentjen, Frank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293334/ https://www.ncbi.nlm.nih.gov/pubmed/37131100 http://dx.doi.org/10.1007/s10620-023-07950-0 |
Ejemplares similares
-
Clinical management of the most common extra-intestinal
manifestations in patients with inflammatory bowel disease focused on the
joints, skin and eyes
por: Jansen, Fenna M, et al.
Publicado: (2020) -
Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era?
por: Gargallo-Puyuelo, Carla J., et al.
Publicado: (2021) -
Thiopurine Methyltransferase Activity and Thiopurine Metabolites in Inflammatory Bowel Disease
por: El-Matary, Wael
Publicado: (2020) -
Analytical Pitfalls of Therapeutic Drug Monitoring of Thiopurines in Patients With Inflammatory Bowel Disease
por: Simsek, Melek, et al.
Publicado: (2017) -
Allopurinol and 5-aminosalicylic acid influence thiopurine-induced hepatotoxicity in vitro
por: Broekman, Mark M. T. J., et al.
Publicado: (2015)